8 completed, 2 recruiting, 2 terminated, 1 unknown. 13 Phase 1, 10 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 13 | Completed 8, Recruiting 2, Terminated 2, Unknown 1 |
| Phase 2 | 10 | Completed 6, Recruiting 2, Terminated 2 |
Follow Blindness: new trials by email Literature Review of Blindness trials Research Report on Blindness
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO) OpCT-001 - Primary Photoreceptor Disease, Retinitis Pigmentosa (RP) | Phase 1 / Phase 2 | Recruiting | BlueRock Therapeutics | 54 | 2025-03-10 | 2026-10-15 |
| BF844 Safety and Pharmacokinetic Study in Healthy Volunteers BF844 - Usher Syndrome Type 3 | Phase 1 | Unknown | EyeXCel Pty. Ltd. | 76 | 2024-09-09 | 2024-09-19 |
| Study of Subretinally Injected AAVB-081 in Patients With Usher Syndrome Type IB (USH1B) Retinitis Pigmentosa AAVB-081 - Usher Syndrome, Type 1B | Phase 1 / Phase 2 | Recruiting | AAVantgarde Bio Srl | 15 | 2024-07-02 | 2025-05-02 |
| Safety and Efficacy of NPI-001 Tablets for RP Associated With Usher Syndrome NPI-001, Placebo - Usher Syndromes | Phase 1 / Phase 2 | Completed | Nacuity Pharmaceuticals, Inc. | 49 | 2020-09-03 | 2026-07-01 |
| Extension Study to Study PQ-110-001 (NCT03140969) QR-110 - Leber Congenital Amaurosis 10, Blindness | Phase 1 / Phase 2 | Terminated | Laboratoires Thea | 9 | 2019-05-13 | 2024-10-15 |
| Study to Evaluate Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene QR-421a, Sham-procedure (dose cohort 1&2 only) - Retinitis Pigmentosa, Usher Syndrome Type 2 | Phase 1 / Phase 2 | Completed | ProQR Therapeutics | 20 | 2019-03-06 | 2022-04-20 |
| ADVM-022 Intravitreal Gene Therapy for Wet AMD ADVM-022 - Wet Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration | Phase 1 | Completed | Adverum Biotechnologies, Inc. | 30 | 2018-11-14 | 2023-08-08 |
| A Clinical Trial of Dantrolene Sodium in Pediatric and Adult Patients With Wolfram Syndrome dantrolene sodium - Wolfram Syndrome, Diabetes Mellitus | Phase 1 / Phase 2 | Completed | Washington University School of Medicine | 21 | 2017-01-01 | 2024-03-13 |
| Combined tDCS and Vision Restoration Training in Post-acute Stroke: an Exploratory Efficacy and Safety Study verum tDCS, sham tDCS, VRT - Hemianopia, Stroke | Phase 1 / Phase 2 | Completed | University of Magdeburg | 19 | 2013-03-01 | 2016-03-09 |
| Combined tDCS and Vision Restoration Training in Subacute Stroke Rehabilitation: A Pilot Study tDCS, Standard rehabilitation - Hemianopia, Stroke | Phase 1 / Phase 2 | Completed | University of Magdeburg | 14 | 2013-01-01 | 2016-10-17 |
| Study of SAR421869 in Participants With Retinitis Pigmentosa Associated With Usher Syndrome Type 1B SAR421869 - Usher Syndrome, Retinitis Pigmentosa | Phase 1 / Phase 2 | Terminated | Sanofi | 9 | 2012-03-26 | 2022-04-28 |
| Computer Vision System for the Blind Veteran initial system, modified system - Blindness | Phase 1 | Completed | VA Office of Research and Development | 16 | 2011-11-01 | 2016-01-22 |
| Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid Rituximab - Ocular Cicatricial Pemphigoid | Phase 1 / Phase 2 | Completed | University of Alabama at Birmingham | 3 | 2006-01-01 | 2026-05-04 |
Usher Syndromes (6) · Retinitis Pigmentosa (4) · Eye Diseases (3) · Retinal Diseases (3) · Eye Abnormalities (2) · Eye Diseases, Hereditary (2) · Hemianopsia (2) · Retinal Degeneration (2) · Stroke (2) · Vision Disorders (2) · Ataxia (1) · Cone-Rod Dystrophies (1) · Diabetes Mellitus (1) · Leber Congenital Amaurosis (1)
Nervous System Diseases (13) · Pathological Conditions, Signs and Symptoms (13) · Signs and Symptoms (13) · Neurologic Manifestations (12) · Sensation Disorders (12) · Vision Disorders (11) · Eye Diseases (10) · Congenital Abnormalities (8) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (8) · Genetic Diseases, Inborn (8) · Abnormalities, Multiple (7) · Deaf-Blind Disorders (7) · Deafness (7) · Ear Diseases (7)
Dantrolene (1) · Intravitreal Injections (1) · Rituximab (1) · Transcranial Direct Current Stimulation (1)
University of Magdeburg (2) · AAVantgarde Bio Srl (1) · Adverum Biotechnologies, Inc. (1) · BlueRock Therapeutics (1) · EyeXCel Pty. Ltd. (1) · Laboratoires Thea (1) · Nacuity Pharmaceuticals, Inc. (1) · ProQR Therapeutics (1) · Sanofi (1) · University of Alabama at Birmingham (1) · VA Office of Research and Development (1) · Washington University School of Medicine (1)
United States (8) · Australia (2) · Austria (2) · France (2) · Germany (2) · Belgium (1) · Canada (1) · Italy (1) · United Kingdom (1)
Benedict Tan, MBBS, FRACP (1) · Bernhard A Sabel, Prof. Dr. (1) · Cha-Min Tang, PhD MD (1) · Craig A Elmets (1) · Fumihiko Urano, MD (1) · Jose-Alain Sahel, MD, PhD (1) · Lee Anderson, MD (1) · Raimund Alber, MS (1) · Richard Weleber, MD (1)
PMID 24705452, PMID 28082176, PMID 31215818, PMID 34185708, PMID 37418643, PMID 38152412
2018 (2), R21DK113487 (1)